Zhengye Biotechnology Holding Ltd income statement

In fiscal 2025, Zhengye Biotechnology Holding Ltd reported revenue of $16.2m, down 37.5% on the year before, operating income of −$9.8m (a -60.6% margin) and net income of −$9.7m. Every line below comes from the company's 10-K and 10-Q filings; column headings link to the filing.

Income statement

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Zhengye Biotechnology Holding Ltd: income statement, annual
Fiscal year	2022Dec 2022	2023Dec 2023	2024Dec 2024	2025Dec 2025
Revenue	39	30	26	16
Cost of revenue	17	13	13	13
Gross profit	22	17	13	3
Research and development	2	2	2	3
Selling and marketing	5	6	6	6
General and administrative	4	3	3	4
Operating income	10	6	2	−10
Interest expense	0	1	1	0
Income before tax	10	6	2	−10
Income tax	1	1	0	2
Net income	7	4	2	−10
Diluted EPS	$0.15	$0.10	$0.03	—
Diluted shares (average)	46m	46m	46m	47m
EBITDA	13	10	6	−6

EBITDA is operating income plus depreciation and amortisation. EPS and share counts are restated for stock splits. A dash means the company did not report the line for that period; expense lines are shown as reported, so they need not add up to the totals when a company reports other items between them.

Compare with peers

Head to head: SLGL vs ZYBT JAGX vs ZYBT VRCA vs ZYBT

More: Pharmaceuticals stocks compared, Health Care sector, rankings of US companies

Figures from Zhengye Biotechnology Holding Ltd's SEC filings (10-K and 10-Q). How we read and check them: methodology and data sources. Not investment advice. Back to Zhengye Biotechnology Holding Ltd.